KLF15: A Potential Drug Target and Biomarker (G28999)

Target Name: KLF15

NCBI ID: G28999

KLF15

KLF15: A Potential Drug Target and Biomarker

Kruppel-like factor 15 (KLF15), also known as transcript variant X4, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. KLF15 is a key regulator of gene expression and has been shown to play a role in a variety of biological processes, including cell growth, differentiation, and survival.

The KLF15 gene was first identified in the genomic database by researchers at the University of California, San Diego, and is located on chromosome 16. The protein encoded by the gene is a transcription factor, named KLF15. KLF15 plays an important role in the cell cycle and is a key regulator of the cell cycle. The protein expression level of KLF15 is altered in various cancers and is closely related to tumor occurrence and progression.

Currently, KLF15 is considered a potential drug target. Researchers are exploring the role of KLF15 in tumor treatment and investigating its value as a tumor biomarker. Several studies have demonstrated the effectiveness of KLF15 in treating a variety of cancers, including breast, lung, prostate and lymphoma.

The tumor suppressor effect of KLF15 is achieved through multiple pathways. First, KLF15 can inhibit the cell cycle and hinder the proliferation of tumor cells. Secondly, KLF15 can regulate cell apoptosis and promote cell self-destruction, thereby inhibiting the growth of tumor cells. In addition, KLF15 can also regulate cell signaling pathways, thereby inhibiting the invasion and metastasis of tumor cells.

The biological function of KLF15 is not only meaningful in tumor treatment, but also can be used as a biomarker of tumors. The expression level of KLF15 can be used as a predictor of tumor recurrence. In addition, the expression level of KLF15 is also related to the survival rate of tumor patients. Therefore, studying the biological functions of KLF15 and in-depth understanding of its role in tumor treatment and monitoring are of great significance for the development of clinical cancer treatment.

In summary, KLF15 is a molecule with broad biological functions and can serve as a potential drug target. By studying the role of KLF15 in tumor treatment and monitoring, better treatment options and survival prospects can be provided for tumor patients.

Protein Name: KLF Transcription Factor 15

Functions: Transcriptional regulator that binds to the GA element of the CLCNKA promoter. Binds to the KCNIP2 promoter and regulates KCNIP2 circadian expression in the heart (By similarity). Is a repressor of CCN2 expression, involved in the control of cardiac fibrosis. It is also involved in the control of cardiac hypertrophy acting through the inhibition of MEF2A and GATA4 (By similarity). Involved in podocyte differentiation (By similarity). Inhibits MYOCD activity. Is a negative regulator of TP53 acetylation. Inhibits NF-kappa-B activation through repression of EP300-dependent RELA acetylation

The "KLF15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLF15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets